Promoter Polymorphism (rs12770170, -184C/T) of Microseminoprotein, Beta as a Risk Factor for Benign Prostatic Hyperplasia in Korean Population
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Benign prostatic hyperplasia (BPH) is the most common prostate disease in aging men. Microseminoprotein-beta (MSMB) is abundant in semen. In this study, we investigated association between single nucleotide polymorphisms (SNPs) at the promoter of the MSMB gene and the risk for developing BPH in a Korean population. Methods: We genotyped two promoter polymorphisms (rs12770171, -184C/T and rs10993994, -2C/T) of the MSMB gene by direct sequencing. Ninety-five BPH patients and 78 control subjects were recruited for this study. SNPStats and Haploview version 4.2 were used for genetic analyses. Multiple logistic regression models (codominant, dominant, recessive, and log-additive models) were applied to determine the odds ratio (OR), 95% confidence interval (CI), and P-value. Results: Genotype frequency of the rs12770171 SNP showed significant difference between BPH patients and controls (OR, 2.14; 95% CI, 1.07–4.27; P=0.032 in the codominant 1 model; OR, 2.31; 95% CI, 1.19–4.47; P=0.011 in the dominant model; and OR, 2.05; 95% CI, 1.17–3.61; P=0.009 in the log-additive model). Moreover, the SNP also showed association between the two groups (OR, 2.05; 95% CI, 1.19–3.52; P=0.009). The rs10993994 SNP was not associated with BPH. In haplotype analysis, CC and TT haplotypes were associated with BPH (P<0.05). Conclusions: This result indicates that a promoter polymorphism (rs12770170, -184C/T) in the MSMB gene may be associated with BPH development in a Korean population.
Abstract
Purpose: Benign prostatic hyperplasia (BPH) is the most common prostate disease in aging men. Microseminoprotein-beta (MSMB) is abundant in semen. In this study, we investigated association between single nucleotide polymorphisms (SNPs) at the promoter of the MSMB gene and the risk for developing BPH in a Korean population. Methods: We genotyped two promoter polymorphisms (rs12770171, -184C/T and rs10993994, -2C/T) of the MSMB gene by direct sequencing. Ninety-five BPH patients and 78 control subjects were recruited for this study. SNPStats and Haploview version 4.2 were used for genetic analyses. Multiple logistic regression models (codominant, dominant, recessive, and log-additive models) were applied to determine the odds ratio (OR), 95% confidence interval (CI), and P-value. Results: Genotype frequency of the rs12770171 SNP showed significant difference between BPH patients and controls (OR, 2.14; 95% CI, 1.07–4.27; P=0.032 in the codominant 1 model; OR, 2.31; 95% CI, 1.19–4.47; P=0.011 in the dominant model; and OR, 2.05; 95% CI, 1.17–3.61; P=0.009 in the log-additive model). Moreover, the SNP also showed association between the two groups (OR, 2.05; 95% CI, 1.19–3.52; P=0.009). The rs10993994 SNP was not associated with BPH. In haplotype analysis, CC and TT haplotypes were associated with BPH (P<0.05). Conclusions: This result indicates that a promoter polymorphism (rs12770170, -184C/T) in the MSMB gene may be associated with BPH development in a Korean population.
참고문헌 (24)
- 김수강, "Toll-Like Receptor 10-1-6 Gene Cluster Polymorphisms Are Not Associated With Benign Prostatic Hyperplasia in Korean Population", International Neurourology Journal, 18(1), pp.10~15 (2014), 대한배뇨장애요실금학회
- Hoke GP, "Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations", Am J Med, 121(8 Suppl 2), pp.S3~S10 (2008)
- Mikolajczyk SD, "Are multiple markers the future of prostate cancer diagnostics?", Clin Biochem, 37, pp.519~528 (2004)
- Sanda MG, "Genetic susceptibility of benign prostatic hyperplasia", J Urol, 152, pp.115~119 (1994)
- Madigan MP, "CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China", Int J Cancer, 107, pp.271~275 (2003)
- Novelli G, "Pharmacogenetics of human androgens and prostatic diseases", Pharmacogenomics, 2, pp.65~72 (2001)
- 석호식, "Association of a Missense ALDH2 Single Nucleotide Polymorphism (Glu504Lys) With Benign Prostate Hyperplasia in a Korean Population", International Neurourology Journal, 17(4), pp.168~173 (2013), 대한배뇨장애요실금학회
- El Ezzi AA, "Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among Lebanese men", Asian Pac J Cancer Prev, 15, pp.1255~1262 (2014)
- Yoo KH, "Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia", Asian J Androl, 12, pp.690~696 (2010)
- Lilja H, "Three predominant proteins secreted by the human prostate gland", Prostate, 12, pp.29~38 (1988)
- Ulvsback M, "Molecular cloning of a small prostate protein, known as beta-microsemenoprotein, PSP94 or beta-inhibin, and demonstration of transcripts in non-genital tissues", Biochem Biophys Res Commun, 164, pp.1310~1315 (1989)
- Dube JY, "Isolation from human seminal plasma of an abundant 16-kDa protein originating from the prostate, its identification with a 94-residue peptide originally described as beta-inhibin", J Androl, 8, pp.182~189 (1987)
- Whitaker HC, "The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target", Prostate, 70, pp.333~340 (2010)
- Garde SV, "Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis", Prostate, 38, pp.118~125 (1999)
- Reeves JR, "Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy", Clin Cancer Res, 12(20 Pt 1), pp.6018~6022 (2006)
- Chan PS, "In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates", Prostate, 41, pp.99~109 (1999)
- Gabriel SB, "The structure of haplotype blocks in the human genome", Science, 296, pp.2225~2229 (2002)
- Sutcliffe S, "MSMB variation and prostate cancer risk: clues towards a possible fungal etiology", Prostate, 74, pp.569~578 (2014)
- Lou H, "Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB", NCOA4 fusion transcripts, 2012, pp.131, 1453~1466
- Pomerantz MM, "Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis", PLoS Genet, 6, pp.e1001204~ (2010)
- Orsted DD, "The link between benign prostatic hyperplasia and prostate cancer", Nat Rev Urol, 10, pp.49~54 (2013)
- Lou H, "Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility", Proc Natl Acad Sci, 106, pp.7933~7938 (2009)
- Thomas G, "Multiple loci identified in a genome-wide association study of prostate cancer", Nat Genet, 40, pp.310~315 (2008)
- Nam RK, "A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis", J Urol, 175, pp.1291~1297 (2006)